

BILLING AND CODING GUIDE

Possible coding options for COSELA for injection, for intravenous use

» PERMANENT J CODE

Effective: 10/1/2021

HCPCS Level II code:

J1448 Injection, trilaciclib, 1 mg

CPT[®] code:

96365 Intravenous (IV) infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

FIND IN THIS GUIDE

- Overview of codes (NDC, ICD-10-CM, CPT, and HCPCS)
- COSELA Cares[™] information

This guide provides coding and reimbursement information for COSELA[®] (trilaciclib)

Pharmacosmos Therapeutics provides this material for informational purposes only. This material is not an affirmative instruction as to the appropriate code(s) and modifier(s) to use for a particular service, supply, procedure, or treatment. Physicians and providers are responsible for determining and submitting appropriate codes, modifiers, and claims for all services they render and for determining that those services were reasonable and necessary. Actual codes and/or modifiers used are done so at the sole discretion of the treating physician or facility. You should contact your local payor for the most recent and specific coding and coverage guidelines, and reimbursement applicable to you. Pharmacosmos Therapeutics makes no guarantee regarding medical benefit coverage or reimbursement from any payor. Information included in this material was obtained from third-party sources and is accurate as of the time of its publication but is subject to change without notice.

CPT codes, descriptions, and other data only are copyright 2026 American Medical Association. All Rights Reserved. Applicable FARS/HHSAR apply.

» Summary of Possible Billing and Coding for COSELA® (trilaciclib)

Important codes include the following:

PRODUCT DESCRIPTION¹	COSELA® (trilaciclib) 300 mg (equivalent to 349 mg of trilaciclib dihydrochloride)
HCPCS LEVEL II CODE	J1448 Injection, trilaciclib, 1 mg; effective: 10/1/2021
CPT® CODE	96365 Intravenous infusion for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

» ICD-10-CM Diagnosis Codes

Primary Diagnosis Codes

The following ICD-10-CM codes may describe diagnoses for patients treated with COSELA.

ICD-10-CM	DESCRIPTION
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C7A.090	Malignant carcinoid tumor of the bronchus and lung

Secondary Diagnosis Codes

The following ICD-10-CM codes may accompany primary diagnoses for patients treated with COSELA.

ICD-10-CM	DESCRIPTION
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C7A	Malignant neuroendocrine tumors
C7A.0	Malignant carcinoid tumors
C7B	Secondary neuroendocrine tumors
C77	Secondary and unspecified malignant neoplasm of lymph nodes
C78	Secondary malignant neoplasm of respiratory and digestive organs
C79	Secondary malignant neoplasm of other and unspecified sites

» Supporting Codes

Z codes are used to document patients with potential health hazards related to family and personal history and certain conditions influencing health status.

Z CODE	DESCRIPTION
Z87.891	Personal history of nicotine dependence
Z51.11	Encounter for antineoplastic chemotherapy
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic, and related tissues

» Current Procedural Terminology (CPT®) Codes

The chart below lists the potential CPT code for your reference when submitting claims for COSELA® (trilaciclib).

CPT CODE	DESCRIPTION
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

» Healthcare Common Procedure Coding System (HCPCS)

HCPCS CODE	DESCRIPTION
J1448	Injection, trilaciclib, 1 mg
MODIFIERS	
JW ^a	Drug amount discarded/not administered to any patient
JZ ^b	Zero drug amount discarded/not administered to any patient

NOTE: Under CMS requirements, you may be reimbursed for both administered and discarded product up to the labeled amount of the product. For more information on the JW and JZ modifiers, visit [CMS.gov](https://www.cms.gov).

» National Drug Code (NDC)

COSELA NDC numbers are listed below. Please note that converting the 10-digit NDC to an 11-digit NDC requires the use of a leading zero in the product code or middle section of the NDC.

COSELA PACKAGE SIZE	NDC
3 in. x 1.5 in. (carton size)	10-digit: 73462-101-01 ^c or 73594-0101-1 ^d
	11-digit: 73462-0101-01 ^c or 73594-0101-01 ^d
DISPENSING PACK QUANTITY	1 vial/carton
UPC NUMBER	37346210101 ^c or 37359401011 ^d

^aEffective January 1, 2017, the JW modifier must be used to report discarded amounts of a single-dose container drug in order to obtain payment for a discarded amount of drug from single-dose or single-use packaging.

^bEffective July 1, 2023, Medicare requires the JZ modifier on all claims for single-dose containers where there are no discarded amounts.

^cThese NDCs contain the previous labeler code, 73462, and will remain in inventory until expiry. This UPC corresponds to these NDCs.

^dThese NDCs contain the Pharmacosmos Therapeutics Inc. labeler code, 73594. This UPC corresponds to these NDCs.

CPT codes, descriptions, and other data only are copyright 2026 American Medical Association. All Rights Reserved.
Applicable FARS/HHSAR apply.

Reference: 1. COSELA (trilaciclib). Prescribing Information. Pharmacosmos Therapeutics Inc.; 2025.

Please see Important Safety Information on page 5 and Full Prescribing Information.

COSELA
trilaciclib for injection
300 mg



The COSELA Cares™ Patient Support Program

Your single source for access and affordability solutions

COSELA Cares offers a suite of solutions to help you address access and reimbursement hurdles



Benefits verification to confirm patient coverage and out-of-pocket responsibilities



Providing resources that connect eligible patients, regardless of insurance type, to appropriate support options for high deductibles, copays, or coinsurance^a



Payor-specific guidance for prior authorizations and appeals



Help eligible patients who meet program criteria access COSELA treatment and support resources



Assistance navigating insurance-related delays or coverage denials

For your eligible commercial patients, copay assistance is available through separate enrollment at [COSELAcopay.com](https://www.coselahcp.com/cosela-copay)



Complete and submit the form to enroll patients in COSELA Cares.

Download the enrollment form at www.coselahcp.com/cosela-cares.

Fax the completed form to 1-833-329-4121.




Call us with questions at 1-833-418-6663, Monday – Friday, 8 AM – 6 PM ET.



Or email us at enroll@COSELAcares.com.

^aCOSELA Cares provides informational support only and does not submit claims or perform administrative services on behalf of providers. Program participation does not guarantee insurance coverage, product access, or reimbursement. Eligibility and restrictions apply.



SCAN HERE to visit
www.coselahcp.com/cosela-cares
for additional information.



INDICATION

COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

- COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib.

WARNINGS AND PRECAUTIONS

Injection-Site Reactions, Including Phlebitis and Thrombophlebitis

- COSELA administration can cause injection-site reactions, including phlebitis and thrombophlebitis, which occurred in 56 (21%) of 272 patients receiving COSELA in clinical trials, including Grade 2 (10%) and Grade 3 (0.4%) adverse reactions. Monitor patients for signs and symptoms of injection-site reactions, including infusion-site pain and erythema during infusion. For mild (Grade 1) to moderate (Grade 2) injection-site reactions, flush line/cannula with at least 20 mL of sterile 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP after end of infusion. For severe (Grade 3) or life-threatening (Grade 4) injection-site reactions, stop infusion and permanently discontinue COSELA. Injection-site reactions led to discontinuation of treatment in 3 (1%) of the 272 patients.

Acute Drug Hypersensitivity Reactions

- COSELA administration can cause acute drug hypersensitivity reactions, which occurred in 16 (6%) of 272 patients receiving COSELA in clinical trials, including Grade 2 reactions (2%). Monitor patients for signs and symptoms of acute drug hypersensitivity reactions. For moderate (Grade 2) acute drug hypersensitivity reactions, stop infusion and hold COSELA until the adverse reaction recovers to Grade $\leq$ 1. For severe (Grade 3) or life-threatening (Grade 4) acute drug hypersensitivity reactions, stop infusion and permanently discontinue COSELA.

Interstitial Lung Disease/Pneumonitis

- Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin-dependent kinases (CDK)4/6 inhibitors, including COSELA, with which it occurred in 1 (0.4%) of 272 patients receiving COSELA in clinical trials. Monitor patients for pulmonary symptoms of ILD/pneumonitis. For recurrent moderate (Grade 2) ILD/pneumonitis, and severe (Grade 3) or life-threatening (Grade 4) ILD/pneumonitis, permanently discontinue COSELA.

Embryo-Fetal Toxicity

- Based on its mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use an effective method of contraception during treatment with COSELA and for at least 3 weeks after the final dose.

ADVERSE REACTIONS

- Serious adverse reactions occurred in 30% of patients receiving COSELA. Serious adverse reactions reported in >3% of patients who received COSELA included respiratory failure, hemorrhage, and thrombosis.
- Fatal adverse reactions were observed in 5% of patients receiving COSELA. Fatal adverse reactions for patients receiving COSELA included pneumonia (2%), respiratory failure (2%), acute respiratory failure (<1%), hemoptysis (<1%), and cerebrovascular accident (<1%).
- Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received COSELA. Adverse reactions leading to permanent discontinuation of any study treatment for patients receiving COSELA included pneumonia (2%), asthenia (2%), injection-site reaction, thrombocytopenia, cerebrovascular accident, ischemic stroke, infusion-related reaction, respiratory failure, and myositis (<1% each).
- Infusion interruptions due to an adverse reaction occurred in 4.1% of patients who received COSELA.
- The most common adverse reactions ($\geq$ 10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.

DRUG INTERACTIONS

- COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin).

To report suspected adverse reactions, contact Pharmacosmos Therapeutics at 1-800-790-4189 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive. Please see Full Prescribing Information.

Please see Important Safety Information on page 5
and Full Prescribing Information.

COSELA® and COSELA Cares™ are trademarks of Pharmacosmos Holding A/S.
© 2026 Pharmacosmos Therapeutics Inc. (a Pharmacosmos Group company).
All rights reserved. US-TCB-2400118 V4 06/26

PHARMACOSMOS
THERAPEUTICS

COSELA®
trilaciclib for injection
300 mg